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Hearing lossAbstract Purpose: About 40e60% of patients treated with post-operative radiotherapy for
parotid cancer experience ipsilateral sensorineural hearing loss. Intensity-modulated radio-
therapy (IMRT) can reduce radiation dose to the cochlea. COSTAR, a phase III trial, inves-
tigated the role of cochlear-sparing IMRT (CS-IMRT) in reducing hearing loss.
Methods: Patients (pT1-4 N0-3 M0) were randomly assigned (1:1) to 3-dimensional conformal
radiotherapy (3DCRT) or CS-IMRT by minimisation, balancing for centre and radiation dose
of 60Gy or 65Gy in 30 daily fractions. The primary end-point was proportion of patients with
sensorineural hearing loss in the ipsilateral cochlea of 10 dB bone conduction at 4000 Hz 12
months after radiotherapy compared using Fisher’s exact test. Secondary end-points included
hearing loss at 6 and 24 months, balance assessment, acute and late toxicity, patient-reported
quality of life, time to recurrence and survival.
Results: FromAug 2008 toFeb 2013, 110 patients (54 3DCRT; 56CS-IMRT)were enrolled from
22 UK centres. Median doses to the ipsilateral cochlea were 3DCRT: 56.2Gy and CS-IMRT:
35.7Gy (p < 0.0001). 67/110 (61%) patients were evaluable for the primary end-point; main rea-
sons for non-evaluability were non-attendance at follow-up or incomplete audiology assessment.
At 12 months, 14/36 (39%) 3DCRT and 11/31 (36%) CS-IMRT patients had 10 dB loss
(pZ 0.81). No statistically significant differences were observed in hearing loss at 6 or 24 months
or in other secondary end-points including patient-reported hearing outcomes.
Conclusion: CS-IMRTreduced the radiationdosebelow the accepted tolerance of the cochlea, but
this did not lead to a reduction in the proportion of patients with clinically relevant hearing loss.
ª 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Malignant parotid gland tumours represent 3e6% of
head and neck cancers. Surgery is the mainstay of
treatment [1]. Local recurrences occur in 20e70% of
patients [1e4]. Adjuvant, post-operative radiotherapy of
60e65Gy in 30 fractions given over 6 weeks is recom-
mended for patients with high risk of recurrence [5,6].
The ipsilateral cochlea is usually very close to the
planning target volume (PTV) and often receives a dose
greater than 50Gy [7] with conventional 3-dimensional
conformal radiotherapy (3DCRT) techniques. As a
consequence, clinically significant high-tone, sensori-
neural hearing loss (>10 dB) has been described in
40e60% of patients after radiotherapy [8e14], peaking
at a frequency around 4000 Hz.
Intensity-modulated radiotherapy (IMRT) produces
highly conformal radiation dose distributions. Cochlear-
sparing IMRT (CS-IMRT) can reduce the dose to the
ipsilateral cochlea, compared with 3DCRT, to below its
accepted tolerance dose of 40e45Gy [7,15]. COSTAR
aimed to investigate whether CS-IMRT reduces senso-
rineural hearing loss.2. Methods
2.1. Study design and participants
COSTAR is a phase III, parallel group, randomised
controlled trial. Patients aged 18 years, WHO perfor-
mance status 0e1 with histologically confirmedmalignant
primary parotid tumours (pT1-4, N0-3, M0) requiring
post-operative adjuvant radiotherapy, were eligible.
Exclusion criteria included previous head and neck
radiotherapy, pre-existing severe hearing loss (hearing
level of>60dB in bone conduction threshold at 4000Hz in
ipsilateral cochlea) and need for chemotherapy. Patients
were staged by diagnostic computed tomography (CT) or
magnetic resonance imagingof headandneck andchestX-
ray or CT of thorax. Resection status was documented
from histopathology as R0 (resection margin>5 mm), R1
(1e5mm)orR2 (<1mm).Patientswere required toattend
long-term follow-up including audiograms and provide
written informed consent.
COSTAR (CRUK/08/004; ISRCTN81772291) was
approved by a National Research Ethics Committee
(MREC 05/Q0801/183), sponsored by the Royal
C.M. Nutting et al. / European Journal of Cancer 103 (2018) 249e258 251Marsden NHS Foundation Trust and undertaken in
accordance with the principles of Good Clinical
Practice.
The Institute of Cancer Research-Clinical Trials and
Statistics Unit (ICR-CTSU) had overall responsibility for
trial conduct, data collation, central statistical moni-
toring and statistical analyses. The trial was overseen by
an independent Trial Steering Committee. An Indepen-
dent Data Monitoring Committee (IDMC) reviewed
emerging safety and efficacy data in confidence.
2.2. Randomisation
Patients were randomly assigned (1:1) to 3DCRT or CS-
IMRT via a telephone call to the ICR-CTSU. Initially,
treatment allocation used random permuted blocks with
stratification by treatment centre and intended dose
(60Gy or 65Gy). From 14 Apr 2011, after 48 patients
were recruited, minimisation with a random element
(balancing by centre and dose) was used. Clinicians were
not masked to treatment allocation.
2.3. Procedures
After obtaining fully informed written consent, all pa-
tients underwent radiotherapy treatment outlining and
planning, according to the target volume definition
guidelines detailed in Web Appendix 1. Trial quality
assurance of the radiotherapy procedures was under-
taken as part of Radiotherapy Trials Quality Assurance
programme. Before trial entry, every centre completed a
facility questionnaire and a process document. These
defined each centre’s equipment and methods for CT
simulation, treatment planning, delivery and verification
and patient set-up verification (Web appendix 2 p1-2).Fig. 1. Typical dose distributions for 3DCRT (A) and CS-IMRT (B)
dimensional conformal radiotherapy; CS-IMRT, cochlear-sparing inteIn addition, an outlining and planning benchmark case
was submitted by each centre (Fig. 1). All documents
and benchmarks were reviewed by the quality assurance
physicist and Chief Investigator for the quality and
compliance; resubmission based on detailed feedback
was requested when necessary. Once a centre was
approved for trial entry, the first three patients were
submitted for a prospective case review by the Chief
Investigator and physicist. Outlines and plans were
modified when necessary before patients were treated.
Dosimetry audit visits were conducted to each centre
that entered patients to assess the accuracy of treatment
delivery.
Baseline audiograms, a balance assessment and
patient-reported quality of life (QoL) were measured
before treatment. Acute toxicity was measured weekly
during radiotherapy and up to 8 weeks afterwards using
the National Cancer Institute Common Toxicity
Criteria, version 3 (CTCAE, v3.0) [16]. Late radiation
toxicity was measured at 3, 6, 12, 18, 24, 36, 48 and 60
months from the end of radiotherapy using the CTCAE,
v3.0, and the Late Effects of Normal Tissues, Subjective
Objective Management Analytic (LENT-SOMA) [17]
scoring systems. Patient-reported outcomes (PROs)
were measured using the European Organisation for
Research and Treatment of Cancer QLQ-C30 instru-
ment [18], the associated head and neckespecific module
HN35 and the Glasgow Hearing Aid Benefit Profile
Questionnaire (GHABP) [19]. Questionnaire booklets
were completed in clinic before randomisation and at 6,
12, 24 and 60 months from the end of radiotherapy.
Bilateral pure-tone audiograms and a balance
assessment were carried out before radiotherapy, at 6
and 12 months and 2 and 5 years after. Standard pure
tone audiometry was used [20]. Audiograms weredemonstrating reduction of radiation dose to cochlea. 3DCRT, 3-
nsity-modulated radiotherapy.
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reported at 4000 Hz. Balance function was documented
using the Romberg test, Unterberger’s step test and the
head thrust test [21e23].
Independent central review of audiograms was per-
formed by Prof. Linda Luxon (Emeritus Professor of
Audiovestibular Medicine and Consultant Neuro-
otologist at the UCL Ear Institute) after the last pa-
tient randomised reached the 12-month time point, with
change in conductive and/or sensorineural hearing loss
between baseline and 12 months categorised as no
change, mild (26e40 dB), moderate (41e60 dB) or se-
vere (>61 dB) [24].
2.4. Outcomes
The primary end-point was a reduction in sensorineural
hearing loss measured by masked bone conduction at
4000 Hz of 10 dB in the cochlea ipsilateral to the pa-
rotid tumour between baseline and 12 months; 12
months was selected a priori as a clinically appropriate
time at which to make a valid assessment of late effects
on hearing [12e14].
Secondary end-points were auditory assessment at 6
and 24 months, acute and late side-effects, patient-
reported QoL and hearing outcomes, balance assess-
ment, time to recurrence (TTR) and overall survival
(OS).
2.5. Statistical analysis
Previous studies suggested the incidence of sensorineural
hearing loss from 3DCRT to be 40e60% [9,12]. Eighty-Fig. 2. CONSORfour patients were required to detect a reduction from
40% to 10% in the proportion suffering sensorineural
hearing loss (90% power, two-sided 5% significance
level).
On 14 March 2012, the IDMC recommended an in-
crease in the sample size to 110 to maintain statistical
power because of a lower than expected proportion of
patients evaluable for the primary end-point.
Analysis was by intention-to-treat, including all pa-
tients with both baseline and 12-month masked bone
conduction threshold assessment. The proportion of
patients with reduction in bone conduction threshold of
10 dB was compared using a Fisher’s exact test. Odds
ratios (ORs) for hearing loss were calculated using lo-
gistic regression (OR<1 in favour of CS-IMRT). Un-
adjusted and adjusted analyses for sex, grade of
differentiation, intended treatment dose, baseline ipsi-
lateral bone conduction threshold and age at random-
isation were performed. Hearing loss by bone and air
conduction testing was summarised by treatment group
using medians and interquartile ranges (IQRs) at each
time point with centrally assessed categorical hearing
loss compared using the Chi-squared test for trend.
Rates of any grade and grade 3 acute and late side-
effects at 12 months were compared using Fisher’s exact
tests. To allow for multiple testing, a significance level of
1% was used for all secondary toxicity and QoL end-
points.
TTR was calculated from randomisation to date of
disease recurrence, or death from parotid cancer,
censored at the second primary cancer diagnosis, death
from other cause or date last seen. OS was calculated
from randomisation to death from any cause, censoredT diagram.
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by log-rank test and hazard ratios (HRs) with 95%
confidence intervals (CIs) obtained from Cox propor-
tional hazards models with HR < 1 favouring CS-
IMRT. The proportionality assumption of the Cox
model held when tested with Schoenfeld residuals.
Analyses are based on a database snapshot taken on
May 18, 2016, and were performed using STATA, v13.
3. Results
3.1. Patients
Between Aug 2008 and Feb 2013, 110 patients were
randomised (3DCRT: 54; CS-IMRT: 56) (Fig. 2) from
22 UK radiotherapy centres (Web appendix 2
TableWA1). Median age at randomisation was 58Table 1
Baseline characteristics and treatment details.
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Median dose to the primary tumour and involved nodes
R0 patients
R1/R2 patients
Median dose to elective nodesa
Mean dose to contralateral cochlea
Mean dose to ipsilateral cochleab,c
Mean dose to contralateral parotid
Maximum dose to brain stem
Maximum dose to spinal cord
3DCRT, 3-dimensional conformal radiotherapy; CS-IMRT, cochlear-spari
Data are mean (range), n (%) or median (IQR; n).
a Only includes patients who received elective nodal irradiation.
b ManneWhitney test p < 0$0001.
c If restricting to patients evaluable for the primary endpoint, mean
median Z 55.4, IQR 41.8e61.9; CS-IMRT n Z 31, median Z 36.1, IQRyears (range 18e88) and 58/110 (53%) patients were
male; 99/110 (90%) patients had R1/R2 resection
status and received 65Gy/30f (Table 1). Randomised
groups were well balanced for the tumour stage and
grade. Median follow-up in living patients was 49.9
months (IQR 37.7e61.9).
3.2. Radiotherapy
Radiotherapy doses are detailed in Table 1. PTV
coverage was not adversely affected by cochlear sparing
in the CS-IMRT arm (Table 1). Median dose to the
ipsilateral cochlea was 56.2Gy with 3DCRT and 35.7Gy
with CS-IMRT (ManneWhitney p < 0.0001). An
additional analysis of the accuracy of the cochlea out-
lining was performed on all patients after the trial was
completed. Maximum doses to the spinal cord and brain3DCRT (N Z 54) CS-IMRT (N Z 56)
59 (19e88) 57 (20e87)
31 (57%) 27 (48%)
23 (43%) 29 (52%)
6 (11%) 3 (5%)
15 (28%) 14 (25%)
32 (59%) 38 (68%)
1 (2%) 1 (2%)
23 (43%) 18 (32%)
9 (17%) 11 (20%)
16 (30%) 21 (38%)
6 (11%) 6 (11%)
16 (30%) 16 (29%)
15 (28%) 22 (39%)
7 (13%) 8 (14%)
12 (22%) 9 (16%)
4 (7%) 1 (2%)
32 (59%) 37 (66%)
4 (7%) 7 (13%)
14 (26%) 9 (16%)
4 (7%) 3 (5%)
65.0 (64.9e65.0; 51) 65.0 (65.0e65.0; 54)
59.1 (58.0 - 60.0; 6) 60.3 (60.0 - 64.9; 3)
65.0 (65.0 - 65.0; 45) 65.0 (65.0 - 65.0; 51)
52.0 (50.0e60.0; 19) 54.4 (54.0e55.4; 20)
6.1 (2.9e8.8; 51) 8.3 (6.6e9.3; 54)
56.2 (44.6e61.0; 51) 35.7 (30.0e39.0; 54)
4.8 (3.0e9.8; 51) 10.8 (9.1e13.5; 54)
35.7 (33.3e40.9; 51) 42.9 (38.6e48.0; 54)
37.3 (32.5e39.0; 51) 40.0 (37.3e42.2; 54)
ng intensity-modulated radiotherapy; IQR, interquartile range.
doses to the ipsilateral cochlea are as follows: 3DCRT n Z 36,
31.9e39.2.
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were higher with CS-IMRT than with 3DCRT
(p Z 0.0022, p Z 0.0001 and p < 0.0001,
respectively) but were within tolerances.
3.3. Hearing impairment and balance assessment
67/110 (61%) patients had paired baseline and 12-month
(masked) bone conduction measurements and were
evaluable for the primary end-point (Table 2). At 12
months after radiotherapy, 25/67 (37%) patients had
10 dB sensorineural hearing loss; 3DCRT: 14/36
(39%), CS-IMRT: 11/31 (35%), p Z 0.81 (Table 2).
Unadjusted and adjusted ORs for hearing loss were 0.86
(95% CI 0.32e2.34) and 0.80 (95% CI 0.27e2.37),
respectively. Proportion with hearing loss 20 dB was
19% with 3DCRT and 16% with CS-IMRT, and loss
30 dB was 8% with 3DCRT and 3% with CS-IMRT.
For air conduction thresholds at 12 months, a loss of
10 dB was seen in 44/86 (51%) patients (3DCRT: 23/42
[55%]; CS-IMRT: 21/44 [48%]; pZ 0.53). No statistically
significant differences in hearing were seen when
measured by bone or air conduction thresholds at either
6 or 24 months (Web appendix 2 Tables WA2 and WA3)
or by centrally assessed hearing loss (Web appendix 2
Table WA4). Balance was not affected by treatment
with no statistically significant differences seen (Table 2).Table 2
Audiometry and vestibular function at 12 months after radiotherapy (prim
Audiometry N with paired data Threshold level (dB) at 4000 Hz Media
Pre-radiotherapy 12 months after radi
Bone conductioneIpsilateral earc
3DCRT 36 30 (10e42.5) 40 (15e50)
CS-IMRT 31 20 (10e45) 35 (15e55)
Air conductioneIpsilateral ear
3DCRT 42 35 (15e55) 50 (20e70)
CS-IMRT 44 25 (10e45) 40 (15e62.5)
Bone conductioneContralateral ear
3DCRT 32 22.5 (10e50) 27.5 (15e50)
CS-IMRT 23 15 (10e40) 20 (5e45)
Air conductioneContralateral ear
3DCRT 42 25 (15e55) 27.5 (20e55)
CS-IMRT 43 25 (10e45) 20 (10e50)










3DCRT, 3-dimensional conformal radiotherapy; CS-IMRT, cochlear-spar
Only includes baseline/12-month data on patients with data from both tim
a Calculated as hearing level at 12 months after radiotherapy (RT) minu
of hearing from pre-RT to 12 months post-RT.
b p-value from Fisher’s exact test comparing proportions with 10 dB
c Primary end-point.3.4. Acute and late radiation toxicity
There were no statistically significant differences be-
tween 3DCRT and CS-IMRT for any acute side-effects
during and up to 8 weeks after radiotherapy (Table 3).
Clinician-assessed late radiation toxicity confirmed
the primary end-point findings with no difference in the
proportion of patients with any CTCAE-grade hearing
toxicity at 12 months (3DCRT: 17/39 [44%]; CS-IMRT:
22/47 [47%]). Dry mouth (any grade) at 12 months was
more prevalent in patients receiving CS-IMRT (38/48,
79%) than 3DCRT (22/43, 51%), pZ 0.008. Similar (but
not statistically significant) differences in dry mouth
were also seen at 18 and 24 months. There were no
statistically significant differences in other late radiation
toxicity scores according to the CTCAE (Table 3), either
at 12 months or when considering the maximum grade
reported during follow-up. No statistically significant
differences in LENT-SOMA hearing domains were seen
at 12 months. However, there was a numerically higher
incidence of salivary gland toxicity with CS-IMRT (37/
48, 77%) than with 3DCRT (27/43, 63%), p Z 0.17.
3.5. PROs and QoL
No statistically significant differences between treatment
groups were seen in any of the four domains of theary end-point).
n (IQR) N with 10 dB loss % p-value for 3DCRT
versus CS-IMRTb
otherapy Changea
5 (-5e15) 14 38.9 0.81
5 (0e10) 11 35.5
10 (0e20) 23 54.8 0.53
5 (0e22.5) 21 47.7
5 (0e10) 9 28.1 0.76
0 (-5e5) 5 21.7
5 (0e5) 9 21.4 0.26
0 (-5e0) 5 11.6







ing intensity-modulated radiotherapy; IQR, interquartile range.
e points available.
s threshold level before RT. A change greater than zero indicates a loss
loss in 3DCRT and CS-IMRT groups.
Table 3
Acute and late toxicity.
3DCRT CS-IMRT p-value for 3DCRT
vs CS-IMRT
N Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 N Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
n % n % n % n % n % n % n % n % n % n % Grade 1 Grade 3
Acute side-effects (CTCAE)a
Hearing 43 19 44% 13 30% 9 21% 2 5% 0 0% 50 30 60% 9 18% 8 16% 3 6% 0 0% 0.15 >0.99
Otitiseexternal ear 51 11 22% 20 39% 18 35% 2 4% 0 0% 54 19 35% 21 39% 14 26% 0 0% 0 0% 0.14 0.23
Otitisemiddle ear 46 19 41% 17 37% 9 20% 1 2% 0 0% 51 27 53% 16 31% 7 14% 1 2% 0 0% 0.31 >0.99
Tinnitus 51 18 35% 0 0% 29 57% 4 8% 0 0% 53 28 53% 0 0% 24 45% 1 2% 0 0% 0.08 0.20
Pain (otalgia) 51 14 27% 20 39% 15 29% 2 4% 0 0% 53 24 45% 17 32% 11 21% 1 2% 0 0% 0.07 0.61
Radiation dermatitis 51 1 2% 1 2% 34 67% 15 29% 0 0% 55 1 2% 9 16% 34 62% 11 20% 0 0% >0.99 0.37
Alopecia 51 6 12% 19 37% 26 51% 0 0% 0 0% 55 2 4% 15 27% 31 56% 7 13% 0 0% 0.31 e
Pharyngeal dysphagia 51 3 6% 16 31% 27 53% 5 10% 0 0% 55 2 4% 15 27% 31 56% 7 13% 0 0% 0.67 0.76
Fatigue 51 1 2% 17 33% 24 47% 9 18% 0 0% 55 3 5% 20 36% 26 47% 6 11% 0 0% 0.62 0.41
Mucositis 51 0 0% 7 14% 30 59% 14 27% 0 0% 55 1 2% 6 11% 33 60% 15 27% 0 0% >0.99 >0.99
Pain (other) 51 0 0% 11 22% 26 51% 14 27% 0 0% 55 2 4% 21 38% 19 35% 13 24% 0 0% 0.50 0.66
Mouth dryness 51 1 2% 16 31% 31 61% 3 6% 0 0% 55 2 4% 19 35% 32 58% 2 4% 0 0% >0.99 0.67
Salivary gland changes 51 5 10% 18 35% 26 51% 2 4% 0 0% 55 3 5% 17 31% 34 62% 1 2% 0 0% 0.48 0.61
Late side-effects (CTCAE)b
Hearing 49 13 27% 15 31% 14 29% 6 12% 1 2% 54 14 26% 20 37% 11 20% 5 9% 4 7% >0.99 0.79
Otitiseexternal ear 50 33 66% 13 26% 3 6% 1 2% 0 0% 54 34 63% 16 30% 4 7% 0 0% 0 0% 0.84 0.48
Otitisemiddle ear 50 33 66% 14 28% 2 4% 1 2% 0 0% 54 36 67% 16 30% 2 4% 0 0% 0 0% >0.99 0.48
Tinnitus 50 21 42% 0 0% 28 56% 1 2% 0 0% 54 28 52% 2 4% 20 37% 4 7% 0 0% 0.33 0.37
Pain (otalgia) 50 32 64% 12 24% 5 10% 1 2% 0 0% 54 38 70% 15 28% 1 2% 0 0% 0 0% 0.54 0.48
Skin pigmentation 49 22 45% 24 49% 3 6% 0 0% 0 0% 54 29 54% 23 43% 2 4% 0 0% 0 0% 0.43 e
Skin atrophy 50 25 50% 24 48% 1 2% 0 0% 0 0% 54 29 54% 24 44% 1 2% 0 0% 0 0% 0.84 e
Skin fibrosis 50 18 36% 27 54% 5 10% 0 0% 0 0% 54 22 41% 30 56% 2 4% 0 0% 0 0% 0.69 e
Mucous membranesefunctional 50 35 70% 10 20% 4 8% 1 2% 0 0% 54 31 57% 18 33% 5 9% 0 0% 0 0% 0.22 0.48
Mucous membraneseclinical examination 50 36 72% 12 24% 2 4% 0 0% 0 0% 54 39 72% 13 24% 2 4% 0 0% 0 0% >0.99 e
Mouth dryness 50 8 16% 29 58% 11 22% 2 4% 0 0% 54 3 6% 39 72% 11 20% 1 2% 0 0% 0.11 0.61
Salivary gland changes 50 13 26% 27 54% 10 20% 0 0% 0 0% 54 12 22% 37 69% 4 7% 1 2% 0 0% 0.82 >0.99
Osteonecrosis 50 49 98% 1 2% 0 0% 0 0% 0 0% 54 53 98% 1 2% 0 0% 0 0% 0 0% >0.99 e
Trismus 50 32 64% 15 30% 3 6% 0 0% 0 0% 54 28 52% 23 43% 3 6% 0 0% 0 0% 0.24 e
Fatigue 50 29 58% 13 26% 5 10% 3 6% 0 0% 53 28 53% 21 40% 4 8% 0 0% 0 0% 0.69 0.11
Late side-effects (LENT-SOMA)c
Ear 50 3 6% 15 30% 10 20% 16 32% 6 12% 54 6 11% 20 37% 10 19% 10 19% 8 15% 0.49 0.32
Subjective hearing 50 8 16% 16 32% 18 36% 7 14% 1 2% 54 11 20% 23 43% 13 24% 6 11% 1 2% 0.62 0.78
Mucosa (oral and pharyngeal) 50 5 10% 22 44% 12 24% 11 22% 0 0% 54 9 17% 27 50% 11 20% 5 9% 2 4% 0.40 0.30
Salivary gland 50 2 4% 20 40% 17 34% 10 20% 1 2% 54 3 6% 21 39% 23 43% 7 13% 0 0% >0.99 0.30
Subjective xerostomia 50 5 10% 23 46% 18 36% 3 6% 1 2% 54 3 6% 30 56% 18 33% 3 6% 0 0% 0.48 0.71
Mandible 50 23 46% 6 12% 17 34% 4 8% 0 0% 54 22 41% 14 26% 18 33% 0 0% 0 0% 0.69 0.05
Teeth 49 39 80% 8 16% 2 4% 0 0% 0 0% 54 41 76% 8 15% 3 6% 2 4% 0 0% 0.81 0.50
Spinal cord 50 45 90% 3 6% 1 2% 1 2% 0 0% 54 47 87% 5 9% 2 4% 0 0% 0 0% 0.76 0.48
Skin 50 3 6% 24 48% 17 34% 6 12% 0 0% 54 3 6% 29 54% 12 22% 10 19% 0 0% >0.99 0.42
3DCRT, 3-dimensional conformal radiotherapy; CS-IMRT, cochlear-sparing intensity-modulated radiotherapy.
a Maximum Common Toxicity Criteria (v3.0) score during and up to 8 weeks after radiotherapy, Table 3.
b Maximum Common Toxicity Criteria (v3.0) score between 3 and 60 months after radiotherapy.
c Maximum LENT-SOMA (Late Effects of Normal Tissues, Subjective Objective Management Analytic) score between 3 and 60 months after radiotherapy. For LENT-SOMA scales, the maximum
















































Fig. 3. Glasgow Hearing Aid Benefit Profile at 12 months after radiotherapy by randomised treatment group.
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related QoL using QLQ-C30 or QLQ-HN35 (Web
appendix 2 Table WA5).3.6. Disease-related outcomes
21/110 (19.1%) patients had a TTR event (3DCRT: 9/54
[16.7%], CS-IMRT: 12/56 [21.4%]). Of these, four had a
locoregional recurrence as the first event (3DCRT: 2;
CS-IMRT: 2), 13 had a distant recurrence (3DCRT: 6,
CS-IMRT: 7) and four died from parotid cancer or
unknown cause without prior recurrence reported
(3DCRT: 1, CS-IMRT: 3). Two-year TTR event-free
rate was 88% (95% CI 75%e94%) with 3DCRT and 88%
(95% CI 76%e95%) with CS-IMRT (p Z 0.75), HR
1.16 (95% CI 0.48e2.79) (Web appendix 2
Figure WA1A).
21/110 (19.1%) patients have died (3DCRT: 11/54
[20.4%], CS-IMRT: 10/56 [17.9%]). Of these, 12 died
from parotid cancer (3DCRT: 7, CS-IMRT: 5). Two-
year OS was 82% (95% CI 69%e90%) with 3DCRT and
92% (95% CI 81%e97%) with CS-IMRT (p Z 0.72),
HR 0.85 (95% CI 0.36e2.01), Web appendix 2
Figure WA1B.4. Discussion
The radiation tolerance of the cochlea is thought to be a
mean dose of 40e45Gy [25,26]. The CS-IMRT tech-
nique evaluated in COSTAR achieved a mean cochlea
dose of 35.7Gy, and 75% of patients randomised to CS-
IMRT received a mean dose of <39Gy (Table 1).
Despite reducing the cochlea dose to less than the
tolerance dose, no statistically significant difference in
masked bone conduction threshold at 4000 Hz was
demonstrated between CS-IMRT and 3DCRT. Sec-
ondary end-points for which a greater proportion ofpatients were evaluable supported the primary end-point
results.
An unexpected finding was that the incidence of late
xerostomia appeared to be higher in patients receiving
CS-IMRT. This could be due to a low-dose bath of
radiation in the oral cavity and oropharynx adversely
affecting the function of minor salivary glands in the
palatal mucosa and causing dry mouth. The contralat-
eral parotid dose was also higher with CS-IMRT
compared with 3DCRT (Table 1).
COSTAR is the only randomised controlled trial to
investigate CS-IMRT. The incidence of hearing loss seen
with 3DCRT was consistent with the 30e50% [3,4,27]
reported in studies not using IMRT. Theunissen et al.
(n Z 36) and Zuur et al. (n Z 101) attempted to mini-
mise cochlear dose (mean 17.8Gy, median 11.4Gy,
respectively) using IMRT and measured hearing before
and after treatment [28,29]. Mean hearing deterioration
in both studies was small and non-significant for fre-
quencies 1000e4000 Hz. However, the incidence of
hearing loss of >10 dB was 36% and 13%, respectively.
A key limitation of COSTAR was that 40% of pa-
tients were not evaluable for the primary end-point
because of audiometry not being performed or masked
bone conduction thresholds not being obtained. The
observed 67 evaluable patients provide reduced but
acceptable power of 80%. The proportion of patients
with 10 dB loss in each treatment group was similar
suggesting it is unlikely that a clinically relevant differ-
ence was missed because of the lack of statistical power.
A more likely reason for the hearing loss seen despite
CS-IMRT is that the previously accepted cochlear
tolerance of 40e45Gy is too high. If this is the case, then
it may be necessary to reduce the cochlea dose much
further to maintain cochlea function. Owing to the short
distance from the edge of the parotid PTV to the co-
chlea, this is unlikely to be possible using IMRT and it
may be that cochlear sparing to very low doses is better
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proton therapy [30].
It is possible, although unlikely, that the mean co-
chlea dose reported in the study is not a true reflection of
the cochlea dose received. A number of factors could
have contributed to this. First, the cochlea could have
been incorrectly localised by the treating physician. On
review of the quality assurance CT data sets, this was
excluded. Second, patient movement could have resul-
ted, by interfraction motion, in a different dose being
delivered to the cochlea than was estimated during
treatment planning. This also seems an unlikely expla-
nation, given that a planning risk volume margin of
3 mm was added to the cochlea organ at risk and that
set-up was checked weekly throughout treatment.
Use of chemotherapy in COSTAR was not permitted.
In locally advanced mucosal squamous cell carcinomas
of the head and neck, where concomitant platinum-
based chemotherapy is the standard of care, auditory
toxicity is even more common. Cochlear sparing could
be tested in a randomised trial in this group, although it
would be difficult to control for chemotherapy intensity.5. Conclusions
CS-IMRT reduced the radiation dose below the
accepted tolerance of the cochlea. CS-IMRT did not
result in statistically or clinically significant reductions
in the proportion of patients with measured or self-
reported hearing loss in the ipsilateral ear at 12 months
after radiotherapy and may increase patient-reported
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